CWA Asset Management Group LLC bought a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) during the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 151,537 shares of the company’s stock, valued at approximately $3,340,000.
Other hedge funds have also added to or reduced their stakes in the company. UMB Bank n.a. increased its position in Teva Pharmaceutical Industries by 555.6% during the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after buying an additional 2,067 shares during the period. Smithfield Trust Co grew its stake in shares of Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after acquiring an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Teva Pharmaceutical Industries in the third quarter valued at about $50,000. Claro Advisors LLC bought a new position in Teva Pharmaceutical Industries during the third quarter worth about $52,000. Finally, Mark Sheptoff Financial Planning LLC bought a new stake in Teva Pharmaceutical Industries in the 2nd quarter valued at about $57,000. 54.05% of the stock is owned by institutional investors and hedge funds.
Insider Activity at Teva Pharmaceutical Industries
In related news, EVP Christine Fox sold 19,388 shares of the stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the transaction, the executive vice president now owns 44,104 shares of the company’s stock, valued at $744,034.48. This represents a 30.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Roberto Mignone sold 286,000 shares of the firm’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the sale, the director now owns 695,000 shares in the company, valued at $15,296,950. This represents a 29.15 % decrease in their position. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades
View Our Latest Report on Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Stock Down 1.0 %
NYSE TEVA opened at $21.03 on Tuesday. Teva Pharmaceutical Industries Limited has a fifty-two week low of $10.83 and a fifty-two week high of $22.80. The business has a fifty day moving average price of $18.66 and a two-hundred day moving average price of $17.91. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. The stock has a market capitalization of $23.83 billion, a PE ratio of -24.74, a PEG ratio of 0.99 and a beta of 0.73.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Featured Articles
- Five stocks we like better than Teva Pharmaceutical Industries
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Build-Your-Bowl Battle: CAVA, Chipotle, and Sweetgreen Face Off
- 3 Fintech Stocks With Good 2021 Prospects
- Insiders Are Loading Up: 3 Key Stock Picks for Investors
- Stock Dividend Cuts Happen Are You Ready?
- How Cigna Remains at the Top of the Health Insurance Food Chain
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.